These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15139055)

  • 41. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.
    Chung KH; Ryu JK; Son JH; Lee JW; Jang DK; Lee SH; Kim YT
    Gut Liver; 2017 Mar; 11(2):298-305. PubMed ID: 27965478
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
    Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
    Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gemcitabine plus nedaplatin as salvage therapy is a favorable option for patients with progressive metastatic urothelial carcinoma after two lines of chemotherapy.
    Matsumoto K; Mochizuki K; Hirayama T; Ikeda M; Nishi M; Tabata K; Okazaki M; Fujita T; Taoka Y; Iwamura M
    Asian Pac J Cancer Prev; 2015; 16(6):2483-7. PubMed ID: 25824784
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
    Mavroudis D; Pappas P; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Nikolaidou M; Samonis G; Marselos M; Georgoulias V
    Ann Oncol; 2003 Feb; 14(2):304-12. PubMed ID: 12562660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
    Cappuzzo F; Novello S; De Marinis F; Franciosi V; Maur M; Ceribelli A; Lorusso V; Barbieri F; Castaldini L; Crucitta E; Marini L; Bartolini S; Scagliotti GV; Crinò L
    Br J Cancer; 2005 Jul; 93(1):29-34. PubMed ID: 15956971
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
    Stadler WM; Halabi S; Rini B; Ernstoff MS; Davila E; Picus J; Barrier R; Small EJ;
    Cancer; 2006 Sep; 107(6):1273-9. PubMed ID: 16909426
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
    Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ;
    J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience.
    De Giorgi U; Rosti G; Papiani G; Aieta M; Fochessati F; Paoluzzi L; Valduga F; Marangolo M
    Am J Clin Oncol; 2004 Oct; 27(5):457-60. PubMed ID: 15596910
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data.
    Airoldi M; Cattel L; Passera R; Pedani F; Delprino L; Micari C
    Am J Clin Oncol; 2006 Oct; 29(5):490-4. PubMed ID: 17023785
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.
    Ch'ang HJ; Lin YL; Wang HP; Chiu YF; Chang MC; Hsu CH; Tien YW; Chen JS; Hsieh RK; Lin PW; Shan YS; Cheng AL; Chang JY; Whang-Peng J; Hwang TL; Chen LT
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e749-57. PubMed ID: 21420250
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.
    Richey SL; Tamboli P; Ng CS; Lin E; Lim ZD; Araujo JC; Jonasch E; Sharma P; Pagliaro LC; Tannir NM
    Am J Clin Oncol; 2013 Oct; 36(5):450-4. PubMed ID: 22706175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
    Katopodis O; Souglakos J; Stathopoulos E; Christopoulou A; Kontopodis E; Kotsakis A; Kalbakis K; Kentepozidis N; Polyzos A; Hatzidaki D; Georgoulias V
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):333-40. PubMed ID: 24930058
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
    Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
    Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.
    Merchan JR; Ferrell A; Macintyre J; Ciombor KK; Levi J; Ribeiro A; Sleeman D; Flores A; Lopes G; Rocha-Lima CM
    Am J Clin Oncol; 2012 Oct; 35(5):446-50. PubMed ID: 21552097
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study.
    Sheng X; Cao D; Yuan J; Zhou F; Wei Q; Xie X; Cui C; Chi Z; Si L; Li S; Mao L; Lian B; Tang B; Yan X; Wang X; Kong Y; Dai J; Bai X; Zhou L; Guo J
    Eur J Cancer; 2018 Sep; 100():1-7. PubMed ID: 29933095
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
    Kalykaki A; Papakotoulas P; Tsousis S; Boukovinas I; Kalbakis K; Vamvakas L; Kotsakis A; Vardakis N; Papadopoulou P; Georgoulias V; Mavroudis D;
    Anticancer Res; 2008; 28(1B):495-500. PubMed ID: 18383891
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study.
    Geoerger B; Chisholm J; Le Deley MC; Gentet JC; Zwaan CM; Dias N; Jaspan T; Mc Hugh K; Couanet D; Hain S; Devos A; Riccardi R; Cesare C; Boos J; Frappaz D; Leblond P; Aerts I; Vassal G;
    Eur J Cancer; 2011 Jan; 47(2):230-8. PubMed ID: 20943374
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial.
    Jo JC; Baek JH; Lee JH; Joo YD; Bae SH; Lee JL; Lee JH; Kim DY; Lee WS; Ryoo HM; Choi Y; Kim H; Lee KH;
    Asia Pac J Clin Oncol; 2016 Jun; 12(2):159-66. PubMed ID: 26956432
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gemcitabine and vinorelbine combination in platinum-sensitive recurrent ovarian cancer.
    Ferrero A; Logrippo V; Spanu PG; Fuso L; Perotto S; Daniele A; Zola P
    Int J Gynecol Cancer; 2009 Dec; 19(9):1529-34. PubMed ID: 19955931
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
    Brell JM; Krishnamurthi SS; Javle M; Saltzman J; Wollner I; Pelley R; Dowlati A; Kantharaj BN; Schluchter MD; Rath L; Ivy SP; Remick SC
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):851-7. PubMed ID: 18670776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.